Frost & Sullivan Awards Genpathway 2008 Healthcare Innovation Award

-Honor recognizes excellence in ChIP, DNA methylation innovation and service-

SAN DIEGO, Oct. 23 /PRNewswire/ -- Genpathway, Inc. announced today that
the company has received the 2008 Frost & Sullivan North American Services in
Drug Discovery Technologies Healthcare Innovation Award.
The award recognizes Genpathway for providing superior services for
chromatin immunoprecipitation (ChIP) and DNA methylation assays that directly
contribute to discoveries in gene regulation, epigenetics, and gene
transcription.
"Frost & Sullivan recognizes Genpathway for its outstanding efforts to
provide researchers an efficient and economical solution to fast-track
notoriously difficult ChIP procedures," explained Frost & Sullivan industry
analyst Christianne Bird. "As the recognized experts in ChIP, Genpathway
consistently is the first to deliver cutting-edge technologies to the market
and teams with top technology providers to offer the newest ChIP techniques
available. For its commitment to providing innovative services to advance life
sciences research and drug discovery and its position as the leader in its
field, Frost & Sullivan is pleased to present Genpathway the 2008 North
America Services in Drug Discovery Technologies Healthcare Innovation Award."
"Genpathway is honored to be recognized with this prestigious award from
Frost & Sullivan," said Mary Harper, PhD, Chief Scientific Officer of
Genpathway. "As interest in and demand for ChIP and DNA methylation assays
continues to expand rapidly, our goal is to provide researchers across a broad
range of disease areas and research fields a fast-track to discovery using our
whole-genome assays. Genpathway's complete ChIP and DNA IP solutions are
proving highly valuable for understanding gene regulation and genetic pathways
by studying transcription factor binding, gene transcription, and epigenetic
events such as DNA methylation and histone modifications."
Frost & Sullivan presents its Annual Award for Innovation in Healthcare to
the company that has introduced truly innovative products, practices, or ideas
within its industry. The award recognizes the company's innovative
contributions that make it possible to envision a new level of care in the
diagnosis, treatment, and management of disease, leading to better outcomes
and quality of life for patients; or that lead to improvements in the tools
that clinicians, diagnosticians, researchers, and healthcare administrators
have at their disposal to improve quality and efficiency in provision of
healthcare services. The selection of this award is based on interviews and
primary market analysis conducted by Frost & Sullivan's industry analyst team.
About Genpathway (www.genpathway.com)
Genpathway is a pharmacogenomics company that provides specialized drug
discovery, research, and development services and develops novel diagnostic
biomarkers that predict drug responses, enabling personalized treatments. The
company applies its proprietary chromatin and methylated DNA
immunoprecipitation (ChIP) technology to understand gene regulation and
genetic pathways by studying transcription factor binding, gene transcription,
and epigenetic events such as DNA methylation and histone modifications. Based
on the information gained from its technology, Genpathway is developing and
commercializing a broad portfolio of clinically validated molecular diagnostic
products and services that will enable the accurate selection of specific
drugs to efficaciously treat individuals with cancer, immune disorders, and
other serious diseases.
About Frost & Sullivan (www.frost.com)
Frost & Sullivan, the Growth Partnership Company, partners with clients to
accelerate their growth. The company's TEAM Research, Growth Consulting, and
Growth Team Membership(TM) empower clients to create a growth-focused culture
that generates, evaluates, and implements effective growth strategies. Frost &
Sullivan employs over 45 years of experience in partnering with Global 1000
companies, emerging businesses, and the investment community from more than 30
offices on six continents. For more information about Frost & Sullivan's
Growth Partnership Services, visit http://www.frost.com.
Contact:
Mary Moynihan
M2Friend Biocommunications
(802) 951-9600
mary@m2friend.com

SOURCE Genpathway, Inc.

Mary Moynihan of M2Friend Biocommunications for Genpathway, Inc.,
+1-802-951-9600, mary@m2friend.com